EntroGen, Inc. products

Many hematologic malignancies carry characteristic chromosomal translocations believed to play an important role in the pathogenesis of these tumors. Chromosomal translocations found in leukemias and lymphomas either fuse enhancer/promoter regions of one gene to another, causing aberrant expression, or by fusing a part of one gene to that of another, resulting in disruption of the normal function of the native genes involved in the translocation, or by gaining new oncogenic functions that promote proliferation and tumorigenesis.Detection of fusion gene transcript expression to assess minimal residual disease (MRD) has been established as an independent prognostic indicator for treatment stratification and patient outcome in many leukemias. Molecular monitoring of patients enables clinicians to initiate therapy at the point of molecular relapse, which has been demonstrated to be beneficial in comparison to therapy adjustments at clinical relapse.